Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,622JPY
1:00am EST
Change (% chg)

¥-56 (-1.20%)
Prev Close
¥4,678
Open
¥4,651
Day's High
¥4,684
Day's Low
¥4,615
Volume
1,967,600
Avg. Vol
2,239,793
52-wk High
¥6,158
52-wk Low
¥4,098

Latest Key Developments (Source: Significant Developments)

Takeda Pharmaceutical to raise up to T$35 mln via private placement
Thursday, 6 Oct 2016 07:12am EDT 

Takeda Pharmaceutical Co Ltd <4502.T>:Says it to issue up to 3,500,000 shares via private placement and to raise up to totally T$35 million.  Full Article

Takeda Pharmaceutical to expand into sub-Saharan Africa - Nikkei<4502.T>
Thursday, 25 Aug 2016 03:17pm EDT 

Nikkei : Takeda Pharmaceutical will expand into sub-Saharan Africa with operations set to reach full swing in next two-to-three years .  Full Article

Ultragenyx files for resale of upto 374,590 shares of co
Wednesday, 10 Aug 2016 06:05pm EDT 

Ultragenyx Pharmaceutical :Files for resale of upto 374,590 shares of co by Takeda Pharma Co ltd/its pledgees, assignees/successor-in-interest.  Full Article

Seattle Genetics-randomized phase 3 clinical trial with ADCETRIS meets primary endpoint
Monday, 1 Aug 2016 06:59am EDT 

Seattle Genetics Inc : Takeda and Seattle Genetics announce positive data from phase 3 Alcanza clinical trial of ADCETRIS® (Brentuximab Vedotin) for CD30-expressing cutaneous T-Cell Lymphoma . Randomized phase 3 clinical trial with ADCETRIS met primary endpoint . Intend to submit a supplemental biologics license application to FDA in first half of 2017 for approval .Phase 3 trial with ADCETRIS demonstrated highly statistically significant improvement in rate of objective response lasting at least 4 months.  Full Article

Fujifilm to bid for Takeda's research reagents unit - Nikkei
Thursday, 21 Jul 2016 01:18pm EDT 

: Fujifilm Holdings is set to make an offer for a laboratory chemicals unit of Takeda Pharmaceutical - Nikkei . Takeda is expected to put Wako Pure Chemical Industries on the chopping block as early as August - Nikkei .Among those interested in Wako Pure Chemical Business are Britain's Permira and other equity funds, as well as a major U.S. medical supplies Co - Nikkei.  Full Article

Takeda working with Nomura Holdings to sell chemicals unit - Bloomberg
Thursday, 21 Jul 2016 10:45am EDT 

:Takeda working with Nomura Holdings to sell chemicals unit, which could fetch more than $1 billion - Bloomberg, citing sources.  Full Article

TiGenix and Takeda enter into licensing agreement for ex-U.S. Rights to CX601
Tuesday, 5 Jul 2016 02:06am EDT 

TiGenix NV : Takeda <4502.T> and TiGenix enter into licensing agreement for ex-u.s. Rights to CX601 for treatment of complex perianal fistulas in patients with crohn's disease . TiGenix will receive an upfront cash payment of 25 million euros ($27.8 million) . TiGenix will be eligible to receive additional regulatory and sales milestone payments for up to a potential total of 355 million euros and double digit royalties on net sales by Takeda . First anticipated milestone payment is 15 million euros upon obtaining marketing authorization of CX601 in European Economic Area (EEA) .In addition, takeda will make an equity investment of 10 million euros in share capital of Tigenix within next 12 months.  Full Article

Takeda Pharmaceutical, Altos Therapeutics to develop Altos's ATC-1906
Friday, 1 Jul 2016 08:00am EDT 

Takeda Pharmaceutical Co Ltd <4502.T> : Co, Altos Therapeutics have entered into agreement to further development of Altos's proprietary compound ATC-1906 . Deal has option for co to acquire Altos from date of agreement, continuing for some time after completion of Phase 1 studies of ATC-1906 . As part of agreement, Takeda will provide Altos an upfront payment for option to acquire Altos . If Takeda elects to exercise option to buy Altos, Takeda would make an additional payment to acquire Altos . Altos would be eligible to receive additional payments linked to clinical development and achievement of key commercial milestones .No further details of agreement were disclosed.  Full Article

Takeda licenses global rights to Theravance Biopharma's TD-8954
Wednesday, 8 Jun 2016 08:00am EDT 

Theravance Biopharma Inc : Takeda Licenses Global Rights To Theravance Biopharma's Td-8954, a novel 5-HT4 agonist and motility agent for gastrointestinal motility disorders . Theravance biopharma inc says will receive an upfront cash payment of $15 million .Will be eligible to receive success based development and sales milestone payments as well as double digit royalties on worldwide net sales by takeda.  Full Article

Ultragenyx, Takeda enter into collaboration to develop, commercialize therapies for rare genetic diseases
Tuesday, 7 Jun 2016 07:00am EDT 

Ultragenyx Pharmaceutical Inc : Ultragenyx and Takeda enter into a collaboration to develop and commercialize therapies for rare genetic diseases . Ultragenyx pharmaceutical inc says to license and develop one or more product candidates from Takeda . Ultragenyx pharmaceutical inc says Takeda to make equity investment in Ultragenyx to fund development . Ultragenyx pharmaceutical inc says Takeda will invest up to $65 million in Ultragenyx in two tranches . A potential third equity investment by Takeda is contingent upon Ultragenyx achieving a specific development milestone on a second asset .Ultragenyx Pharmaceutical Inc says no additional financial details were disclosed.  Full Article

BRIEF-Takeda Pharmaceutical to invest more than 100 mln euros in German dengue vaccine plant

* Says will invest more than 100 million euros in dengue vaccine manufacturing plant in Germany Source text for Eikon: Further company coverage: